Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Published: Aug, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Daewoong Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Daewoong Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Daewoong Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Daewoong Pharmaceutical Co., Ltd.
- The report provides overview of Daewoong Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Daewoong Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Daewoong Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Daewoong Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Daewoong Pharmaceutical Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Daewoong Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Daewoong Pharmaceutical Co., Ltd. Snapshot 7
Daewoong Pharmaceutical Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Daewoong Pharmaceutical Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Daewoong Pharmaceutical Co., Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products Glance 14
Daewoong Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Daewoong Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Daewoong Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Daewoong Pharmaceutical Co., Ltd. - Drug Profiles 20
DWJ-1261 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
nepidermin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
onabotulinumtoxin A 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(olmesartan medoxomil + rosuvastatin calcium) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
DWP-05195 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
DWC-20151 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
DWC-20152 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
DWP-09031 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
DWP-10292 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
DWP-14012 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DWJ-1303 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DWJ-1308 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
DWJ-1325 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DWJ-1340 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DWJ-1351 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DWJ-1355 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
DWJ-1365 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DWJ-1366 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
DWJ-206 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DWJ-208 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DWJ-209 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
DWP-06081 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Protein for Undisclosed Indication 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
DWJ-1367 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DWJ-205 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DWJ-210 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DWP-457 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Daewoong Pharmaceutical Co., Ltd. - Pipeline Analysis 47
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Target 47
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 48
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 49
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 50
Daewoong Pharmaceutical Co., Ltd. - Recent Pipeline Updates 51
Daewoong Pharmaceutical Co., Ltd. - Dormant Projects 52
Daewoong Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 53
Discontinued Pipeline Product Profiles 53
lagociclovir 53
Daewoong Pharmaceutical Co., Ltd. - Company Statement 54
Daewoong Pharmaceutical Co., Ltd. - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Daewoong Pharmaceutical Co., Ltd., Key Information 7
Daewoong Pharmaceutical Co., Ltd., Key Facts 7
Daewoong Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016 9
Daewoong Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 11
Daewoong Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 12
Daewoong Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 13
Daewoong Pharmaceutical Co., Ltd. - Pre-Registration, 2016 14
Daewoong Pharmaceutical Co., Ltd. - Phase III, 2016 15
Daewoong Pharmaceutical Co., Ltd. - Phase II, 2016 16
Daewoong Pharmaceutical Co., Ltd. - Phase I, 2016 17
Daewoong Pharmaceutical Co., Ltd. - Preclinical, 2016 18
Daewoong Pharmaceutical Co., Ltd. - Discovery, 2016 19
Daewoong Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 47
Daewoong Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 48
Daewoong Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 49
Daewoong Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 50
Daewoong Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2016 51
Daewoong Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016 52
Daewoong Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016 53
Daewoong Pharmaceutical Co., Ltd., Other Locations 55
Daewoong Pharmaceutical Co., Ltd., Subsidiaries 56